Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 189

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 189
---
 biomarker panels in various clinical studies, including through collaborations with academic institutions and clinical centers in the US and other countries through Company CEO’s extensive global medical network, expanding therapeutic focus and geographical outreach for the combined company. In approving the Letter of Intent and the Merger, Company’s board of directors considered the pros and cons of the Merger versus other alternatives, which is likely a delisting of Company’s Class A ordinary shares from Nasdaq if the Merger is not completed, and the opportunities and risks presented with the Merger. In particular, Company’s board of directors took into account the following reasons, facts and circumstances in approving the Merger: •the potential for DiamiR’s product candidates in brain health, cancer and inflammatory diseases to create long term value for Company’s stockholders; •the potential synergies available when combining Company’s existing SACT -1therapeutic program for neuroblastoma and potentially other indications with DiamiR’s technology; •the ability of the business combination to facilitate re -commencingof clinic services by the Company including in the growing market of minimally invasive diagnostic solutions for clinical trial support; •the potential enhanced ability to raise capital utilizing a broader potential product portfolio; •Company’s projected cash position and the difficulties the Company has encountered in raising sufficient capital on a stand -alonebasis; •the risks of continuing to operate Company on a stand -alonebasis, including uncertainty regarding Company’s product development and the need to raise significant additional financing for future clinical and commercial development; •the low valuation of the Company on a stand -alonebasis currently evidenced by the trading price of Company’s Class A ordinary shares; •the strategic alternatives to the Merger, including the discussions that Company’s management and advisors previously conducted with other potential partners, and the lack of any viable alternatives; and •the view of Company that the consideration is fair, from a financial point of view, to the holders of Company’s Class A ordinary shares. The Company’s board of directors believed that, as a result of arm’s length negotiations with DiamiR, Company and its management team negotiated the most favorable implied value and equity split for its stockholders that DiamiR was willing to agree to, and that the terms of the Merger Agreement include the most favorable terms to Company in the aggregate to which DiamiR was willing to agree. Immediately prior to signing the Merger Agreement, Company’s stock price was $0.94 per share, as quoted on Nasdaq on July11, 2025. Company and DiamiR